Form 4: Protagonist Therapeutics Director William D. Waddill Reports Stock Transactions

Director William D. Waddill of Protagonist Therapeutics, Inc. reports the acquisition and disposal of common stock and stock options on July 24, 2024.

Summary

• On July 24, 2024, William D. Waddill, a director of Protagonist Therapeutics, Inc., engaged in transactions involving the company's stock.
• Waddill exercised stock options to acquire 8,000 shares of common stock at a price of $12.88 per share.
• Simultaneously, Waddill disposed of 8,000 shares of common stock at a price of $40 per share.
• Following these transactions, Waddill directly owns 12,000 shares of common stock.
• Waddill also owns 8,000 stock options, which are fully vested and exercisable, with an expiration date of September 13, 2026.
• The sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2023.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions appear to be part of a pre-planned trading strategy. The director is still holding a significant amount of shares and options.

Positives

• The director's continued holding of shares and options suggests ongoing confidence in the company.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was planned in advance and not based on immediate market sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.

Stakeholder Impact

• The transactions could influence investor perception of the company's stock, but the impact is likely to be minimal given the pre-planned nature of the trades.

Key Dates